ORIC - Oric Pharmaceuticals, Inc.

QQQ $ 472.49 $ -2.05 (-0.43 %)

DIA $ 416.26 $ -1.07 (-0.26 %)

SPY $ 562.20 $ -1.67 (-0.3 %)

TLT $ 99.62 $ -1.25 (-1.24 %)

GLD $ 235.53 $ -1.83 (-0.77 %)

Previous Close

$ 10.67

Open

Bid

$ 10.67 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 5.27 - $ 16.65

Volume

361,120

Average Volume

Market Cap

752.69M

Beta (5Y Monthly)

$ 1.05

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-06-2024	03-31-2024	10-Q
3	03-11-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	03-16-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-11-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	03-21-2022	12-31-2021	10-K
12	11-08-2021	09-30-2021	10-Q
13	08-10-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-23-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-20-2020	03-31-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on ORIC...
09/18/2024 17:33:28

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...

OpenBench And ORIC Pharmaceuticals Partner...
09/17/2024 16:05:11

Wedbush Reiterates Outperform on ORIC Phar...
09/10/2024 12:58:50

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:19:43

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

Stifel Initiates Coverage On ORIC Pharmace...
09/06/2024 15:28:35

Stifel analyst Bradley Canino initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price...

HC Wainwright & Co. Reiterates Buy on ORIC...
08/14/2024 10:59:21

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...

Wedbush Reiterates Outperform on ORIC Phar...
08/13/2024 14:31:18

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

Oppenheimer Maintains Outperform on ORIC P...
08/13/2024 10:06:50

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price targ...

ORIC Pharmaceuticals Q2 EPS $(0.45) Misses...
08/12/2024 20:18:43

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...

Wedbush Reiterates Outperform on ORIC Phar...
07/17/2024 13:17:41

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...

HC Wainwright & Co. Reiterates Buy on ORIC...
07/17/2024 10:32:32

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...

ORIC Pharmaceuticals Says Entered Into Cli...
07/16/2024 21:01:15

Oppenheimer Maintains Outperform on ORIC P...
07/10/2024 17:20:45

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $17 price t...

Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:43:45

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on...
05/28/2024 13:13:40

Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.

Citigroup Maintains Buy on ORIC Pharmaceut...
05/07/2024 17:37:19

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from...

ORIC Pharmaceuticals Q1 EPS $(0.37) Beats ...
05/06/2024 20:12:25

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of ...

ORIC Pharmaceuticals Announces First Patie...
04/15/2024 20:16:07

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon ...

ORIC Pharmaceuticals Presents Preclinical ...
04/08/2024 12:15:21

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinic...

JP Morgan Maintains Overweight on ORIC Pha...
03/27/2024 14:40:45

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...